Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) EVP Stuart A. Arbuckle sold 6,459 shares of the stock in a transaction on Monday, February 26th. The stock was sold at an average price of $169.00, for a total transaction of $1,091,571.00. Following the completion of the transaction, the executive vice president now directly owns 53,211 shares in the company, valued at approximately $8,992,659. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.
Shares of Vertex Pharmaceuticals Incorporated (VRTX) traded up $0.15 during trading on Thursday, reaching $166.03. 2,055,500 shares of the company’s stock were exchanged, compared to its average volume of 1,904,594. The company has a market cap of $42,115.61, a price-to-earnings ratio of 160.35, a PEG ratio of 2.36 and a beta of 1.61. Vertex Pharmaceuticals Incorporated has a 1-year low of $88.87 and a 1-year high of $174.96. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.14 and a current ratio of 3.28.
Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Wednesday, January 31st. The pharmaceutical company reported $0.61 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.53 by $0.08. Vertex Pharmaceuticals had a net margin of 10.59% and a return on equity of 11.02%. The business had revenue of $651.63 million for the quarter, compared to analyst estimates of $592.49 million. During the same quarter last year, the firm earned $0.35 EPS. The company’s revenue was up 42.1% on a year-over-year basis. sell-side analysts expect that Vertex Pharmaceuticals Incorporated will post 1.67 earnings per share for the current year.
Large investors have recently bought and sold shares of the company. Advisory Services Network LLC lifted its position in shares of Vertex Pharmaceuticals by 337.6% in the 4th quarter. Advisory Services Network LLC now owns 792 shares of the pharmaceutical company’s stock worth $119,000 after purchasing an additional 611 shares during the period. Smithfield Trust Co. purchased a new stake in shares of Vertex Pharmaceuticals in the 3rd quarter worth about $135,000. Whittier Trust Co. lifted its position in shares of Vertex Pharmaceuticals by 153.5% in the 4th quarter. Whittier Trust Co. now owns 991 shares of the pharmaceutical company’s stock worth $149,000 after purchasing an additional 600 shares during the period. FNY Managed Accounts LLC purchased a new stake in shares of Vertex Pharmaceuticals in the 3rd quarter worth about $162,000. Finally, Baldwin Brothers Inc. MA purchased a new stake in shares of Vertex Pharmaceuticals in the 4th quarter worth about $184,000. 94.10% of the stock is owned by hedge funds and other institutional investors.
VRTX has been the topic of several recent research reports. Barclays increased their target price on shares of Vertex Pharmaceuticals from $180.00 to $200.00 and gave the company an “overweight” rating in a report on Thursday, February 1st. HC Wainwright reaffirmed a “hold” rating and set a $103.00 target price on shares of Vertex Pharmaceuticals in a report on Thursday, February 1st. Zacks Investment Research lowered shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Sunday, January 21st. Citigroup reaffirmed a “buy” rating on shares of Vertex Pharmaceuticals in a report on Thursday, February 1st. Finally, Maxim Group reaffirmed a “buy” rating and set a $195.00 target price on shares of Vertex Pharmaceuticals in a report on Wednesday, January 31st. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and twenty-five have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $183.79.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.